Lucid Diagnostics (LUCD) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $1.2M, a 20% sequential and 50% year-over-year increase, driven by higher EsoGuard test volumes and improved consideration per test.

• Completed a robust clinical evidence package for EsoGuard, including peer-reviewed validation studies, enabling imminent Medicare coverage submission.

• Expanded commercial focus to direct contracting, concierge medicine, and employer markets, hiring experienced leaders to drive these initiatives.

• Net loss attributable to common stockholders for Q3 2024 was $12.4M, compared to $14.2M in Q3 2023.

• Substantial doubt exists about the company's ability to continue as a going concern without additional capital or significant revenue growth.

Financial highlights

• Q3 2024 revenue: $1.2M (up 20% sequentially and 50% year-over-year); nine-month revenue: $3.1M.

• Q3 2024 net loss: $12.4M ($0.25/share); non-GAAP net loss per share was $0.20, flat sequentially.

• Cash at September 30, 2024: $14.5M; subsequent financing brings pro forma cash to $28M, providing nearly three quarters of runway at current burn rates.

• Quarterly burn rate was $10.4M, consistent with prior quarters.

• Issued 2.1M shares in Q3 and 3.8M shares in October for debt conversion; total 4.8M shares issued in nine months.

Outlook and guidance

• Poised to submit for Medicare coverage in the coming days, with optimism for a first-half 2025 decision.

• Expecting continued test volume growth, with robust pipelines in direct contracting and concierge medicine.

• Pricing in concierge medicine expected to remain robust, starting at a $2,500 list price.

• Continued recurring losses and negative cash flow from operations are expected in the near term.

• Ability to continue operations depends on raising additional capital and achieving substantial revenue growth.